708 filings
Page 2 of 36
8-K
EVFM
Evofem Biosciences, Inc.
24 Oct 23
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
7:40am
D
EVFM
Evofem Biosciences, Inc.
10 Oct 23
$2.88 mm in debt / options / securities to be acquired, sold $2.88 mm, 14 investors
7:57pm
8-K
EVFM
Evofem Biosciences, Inc.
3 Oct 23
Entry into a Material Definitive Agreement
4:07pm
8-K
EVFM
Evofem Biosciences, Inc.
27 Sep 23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
8:50am
8-K
EVFM
Evofem Biosciences, Inc.
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:49pm
8-K
EVFM
Evofem Biosciences, Inc.
11 Sep 23
Entry into a Material Definitive Agreement
8:01am
DEF 14A
EVFM
Evofem Biosciences, Inc.
Definitive proxy
29 Aug 23
4:00pm
8-K
EVFM
Evofem Biosciences, Inc.
28 Aug 23
Regulation FD Disclosure
4:30pm
PRER14A
EVFM
Evofem Biosciences, Inc.
18 Aug 23
Preliminary revised proxy
4:08pm
8-K/A
EVFM
Evofem Biosciences, Inc.
18 Aug 23
Entry into a Material Definitive Agreement
4:05pm
EFFECT
EVFM
Evofem Biosciences, Inc.
15 Aug 23
Notice of effectiveness
12:15am
10-Q
2023 Q2
EVFM
Evofem Biosciences, Inc.
Quarterly report
14 Aug 23
5:26pm
8-K
EVFM
Evofem Biosciences, Inc.
14 Aug 23
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
5:25pm
424B3
EVFM
Evofem Biosciences, Inc.
14 Aug 23
Prospectus supplement
5:24pm
S-1/A
EVFM
Evofem Biosciences, Inc.
IPO registration (amended)
10 Aug 23
7:28pm
PRE 14A
EVFM
Evofem Biosciences, Inc.
Preliminary proxy
10 Aug 23
6:38pm
8-K
EVFM
Evofem Biosciences, Inc.
10 Aug 23
Entry into a Material Definitive Agreement
5:29pm
CORRESP
EVFM
Evofem Biosciences, Inc.
10 Aug 23
Correspondence with SEC
12:00am
S-1/A
EVFM
Evofem Biosciences, Inc.
IPO registration (amended)
3 Aug 23
5:31pm
CORRESP
EVFM
Evofem Biosciences, Inc.
3 Aug 23
Correspondence with SEC
12:00am